These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy. Akiyama C; Shirai T; Sato H; Fujii H; Ishii T; Harigae H Rheumatol Int; 2022 Jul; 42(7):1271-1280. PubMed ID: 33837447 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126 [TBL] [Abstract][Full Text] [Related]
5. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report. Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993 [TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248 [TBL] [Abstract][Full Text] [Related]
14. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. Hamaguchi Y; Fujimoto M; Matsushita T; Kaji K; Komura K; Hasegawa M; Kodera M; Muroi E; Fujikawa K; Seishima M; Yamada H; Yamada R; Sato S; Takehara K; Kuwana M PLoS One; 2013; 8(4):e60442. PubMed ID: 23573256 [TBL] [Abstract][Full Text] [Related]
15. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Xing X; Li A; Li C Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890 [TBL] [Abstract][Full Text] [Related]
16. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases]. Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111 [No Abstract] [Full Text] [Related]
17. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases]. Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971 [No Abstract] [Full Text] [Related]
18. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657 [TBL] [Abstract][Full Text] [Related]
19. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Yeung TW; Cheong KN; Lau YL; Tse KN Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]